Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Australian Stock Exchange  >  ResApp Health Limited    RAP   AU000000RAP5

RESAPP HEALTH LIMITED

(RAP)
  Report
End-of-day quote. End-of-day quote Australian Stock Exchange - 11/30
0.091 AUD   -1.09%
04/05RESAPP HEALTH : Morgans rates RAP as Add
AQ
2019RESAPP HEALTH : 2019 Letter to Shareholders
PU
2017RESAPP HEALTH : Updated Corporate Governance Policies
PU
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Resapp Health : Dr Philip Currie Joins ResApp's Scientific Advisory Board

08/24/2017 | 07:33am EST
ASX / MEDIA RELEASE Dr Philip Currie Joins ResApp's Scientific Advisory Board Brisbane, Australia, 23 August 2017 -- ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, is pleased to announce the appointment of Dr Philip Currie to its Scientific Advisory Board.

"I am delighted that Dr Currie is joining our Scientific Advisory Board," said Tony Keating, CEO and Managing Director of ResApp Health. "His extensive experience in medical research at leading US hospitals will provide us with invaluable clinical expertise as we move forward with paediatric and adult clinical studies this US winter."

Dr Currie is a cardiologist with more than 35 years in cardiology both in the United States and in Australia with extensive experience in medical research, clinical cardiology and business. Dr Currie completed his medical residency and cardiology fellowship at the Alfred Hospital in Melbourne, followed by cardiology fellowship and staff cardiologist appointment at the Mayo Clinic. Dr Currie was a staff cardiologist for three years at the Cleveland Clinic and then Director of Echocardiography at the Michigan Heart and Vascular Institute for eight years. Dr Currie has been a Principal Investigator on multiple clinical studies at the Alfred Hospital, the Mayo Clinic and the Cleveland Clinic and was a co- investigator on the high-profile multi-centre international clinical trials, CAPRICORN and SERVE-HF. He received his medical degree from Monash University and holds an MBA from the University of Michigan.

ResApp further advises that its CEO and Managing Director, Tony Keating, will be in the US later this week to meet with the SMARTCOUGH-C principal investigators to review protocols and results in detail and to begin planning the subsequent study.

About ResApp Health Limited

ResApp Health Limited (ASX: RAP) is a digital health company developing smartphone applications for the diagnosis and management of respiratory disease. The technology is based on machine learning algorithms that use cough sounds to diagnose and measure the severity of respiratory conditions without the need for additional hardware. The algorithms were initially developed by The University of Queensland with funding from the Bill and Melinda Gates Foundation. ResApp has adult and paediatric clinical studies underway at leading US and Australian hospitals with results demonstrating accurate diagnosis of pneumonia, asthma/reactive airways disease, bronchiolitis, croup and upper respiratory tract infections in children as well as chronic obstructive pulmonary disease, asthma, pneumonia and upper respiratory tract infections in adults. Potential customers

of ResApp's products include healthcare providers in telehealth, emergency department, urgent care and primary care settings as well as global aid and humanitarian organisations in the developing world.

For more information on ResApp, visit www.resapphealth.com.au

Contacts

Dr Tony Keating

CEO and Managing Director

+61 430 180 659

tony@resapphealth.com.au

Mr Brian Leedman Executive Director and

Vice President, Corporate Affairs

+61 412 281 780

brian@resapphealth.com.au

ResApp Health Limited published this content on 23 August 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 24 August 2017 11:32:07 UTC.


© Publicnow 2017
All news about RESAPP HEALTH LIMITED
04/05RESAPP HEALTH : Morgans rates RAP as Add
AQ
2019RESAPP HEALTH : 2019 Letter to Shareholders
PU
2017RESAPP HEALTH : Updated Corporate Governance Policies
PU
2017RESAPP HEALTH (ASX : RAP) talks study results and clinical trials
FI
2017RESAPP HEALTH : Update on Field Evaluation by Médecins Sans Frontières/Doctors W..
PU
2017RESAPP HEALTH : Update on Field Evaluation by Medecins Sans Frontieres
PU
2017RESAPP HEALTH : SMARTCOUGH-C Study and Paediatric Clinical Strategy Update
PU
2017RESAPP HEALTH : Appendix 4E - Preliminary Final Report
PU
2017RESAPP HEALTH : Dr Philip Currie Joins ResApp's Scientific Advisory Board
PU
2017RESAPP HEALTH : Dr Philip Currie Joins ResApp's Scientific Advisory Board
PU
More news
Financials
Sales 2021 2,40 M 1,77 M 1,77 M
Net income 2021 -4,90 M -3,61 M -3,61 M
Net cash 2021 3,10 M 2,28 M 2,28 M
P/E ratio 2021 -15,0x
Yield 2021 -
Capitalization 68,2 M 50,2 M 50,3 M
EV / Sales 2021 27,1x
EV / Sales 2022 5,40x
Nbr of Employees -
Free-Float 85,9%
Chart RESAPP HEALTH LIMITED
Duration : Period :
ResApp Health Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RESAPP HEALTH LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Average target price 0,21 AUD
Last Close Price 0,09 AUD
Spread / Highest target 133%
Spread / Average Target 133%
Spread / Lowest Target 133%
EPS Revisions
Managers
NameTitle
Tony Keating Chief Executive Officer, Executive Director & MD
Roger Aston Non-Executive Chairman
Udantha Abeyratne Chief Scientist
Rob Keniger Vice President-Technology
Christopher Ntoumenopoulos Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
RESAPP HEALTH LIMITED-62.86%50
ORACLE CORPORATION10.87%176 860
SAP SE-15.87%145 293
SERVICENOW INC.91.13%105 247
INTUIT INC.36.23%93 753
DOCUSIGN, INC.191.07%39 942